Pharmacodynamic properties of methotrexate and AminotrexateTM during weekly therapy
- 17 September 2005
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 57 (6) , 826-834
Abstract
4-amino-pteroyl-glutamic acid (AminotrexateTM; AMT) has several advantages over the related antifolate methotrexate (MTX), including greater potency, complete oral bioavailability, and greater accumulation by leukemic blasts in vitro. We compared the pharmacodynamic properties of AMT (given orally at 4 mg/m2 in two divided doses per week) and MTX (100 mg/m2 in four divided doses per week) among children with acute lymphoblastic leukemia. We find AMT and MTX to have equivalent penetration into the bone marrow compartment of these patients, as indicated by the steady-state concentrations within mature red blood cells (RBCs). However, MTX concentrations in the cerebrospinal fluid after oral dosage are significantly greater than AMT. To confirm these clinical observations, mice were treated four weekly injections of AMT or MTX, at a 1:20 dosage ratio, and tissue antifolate content was then determined over the subsequent 22 days. We confirm the selective exclusion of AMT from the CNS compartment, while showing equivalent accumulation of AMT and MTX in the RBCs, liver, spleen, kidneys and testes. Finally, we demonstrate that AMT, MTX, and their predominant polyglutamate species are equipotent inhibitors of their target intracellular enzyme dihydrofolate reductase, emphasizing the critical nature of steady-state tissue accumulation in determining the relative cytotoxic potency of these two antifolates.Keywords
This publication has 31 references indexed in Scilit:
- Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational studyAnnals of the Rheumatic Diseases, 2005
- Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.Blood, 2004
- Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritisArthritis & Rheumatism, 2004
- Accumulation of Methotrexate in Systemic Tissues after Intrathecal AdministrationJournal of Pediatric Hematology/Oncology, 1997
- Transcription of the Human Folylpoly-γ-glutamate Synthetase GeneJournal of Biological Chemistry, 1997
- Mammalian folylpoly-.gamma.-glutamate synthetase. 3. Specificity for folate analogsBiochemistry, 1987
- Pharmacokinetics of methotrexate in erythrocytes in psoriasisEuropean Journal of Clinical Pharmacology, 1984
- Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.Journal of Clinical Investigation, 1983
- The transport and accumulation of methotrexate in human erythrocytesCancer, 1981
- Advances in Chemotherapy of Cancer in Man1956